Table 3.
Characteristics of HCV quasispecies in pre-treatment isolates from SVR and NR patients
| Region and patient type | Genetic distance | dS | dN | dN/dS | Num. amino acid mutations |
| NS5A | |||||
| SVR (n = 99) | 0.1027 | 0.3239 | 0.039 | 0.120 | 33.9 |
| NR (n = 48) | 0.0698 | 0.1216 | 0.025 | 0.206 | 29.8 |
| ISDR | |||||
| SVR (n = 99) | 0.0834 | 0.3084 | 0.0295 | 0.096 | 1.3 |
| NR (n = 48) | 0.0765 | 0.2645 | 0.0271 | 0.102 | 1.9 |
| PKRbd | |||||
| SVR (n = 99) | 0.0934 | 0.2934 | 0.0424 | 0.145 | 5.3 |
| NR (n = 48) | 0.0815 | 0.2694 | 0.0332 | 0.123 | 5.7 |
| V3 | |||||
| SVR (n = 99) | 0.1836 | 0.3264 | 0.1282 | 0.393 | 6.0 |
| NR (n = 48) | 0.1372 | 0.4482 | 0.0556 | 0.124 | 4.7 |
Values were calculated as described in methods; amino acids sequences were compared to HCV-J; n: number of PCR products analyzed; dS: frequency of synonymous substitutions per site; dN: frequency of non-synonymous substitutions per site; SV: Sustained Virological Responders; NR: Non-Responders to IFN-ribavirin therapy.